Search research articles
Contact Us
Filters
Showing results (351-360 of 438) with videos related to
Page
of 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic <i>EGFR</i>-Mutated NSCLC: RELAY Japanese Subset
Kazuto Nishio, Takashi Seto, Makoto Nishio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 5, 2023
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Everett E Vokes, Francoise Mornex, Ahmet Sezer, et al.
ESMO Open
|
January 21, 2020
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
Edward B Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A Socinski, Coleman Obasaju, David Gandara, et al.
Future Oncology (London, England)
|
April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Solange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
JAMA Oncology
|
September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Leora Horn, Ziping Wang, Gang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Page
of 44
Search research articles
Search
Showing results (351-360 of 438) with videos related to
Sort By:
Page
of 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic <i>EGFR</i>-Mutated NSCLC: RELAY Japanese Subset
Kazuto Nishio, Takashi Seto, Makoto Nishio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 5, 2023
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Everett E Vokes, Francoise Mornex, Ahmet Sezer, et al.
ESMO Open
|
January 21, 2020
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
Edward B Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 15, 2016
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A Socinski, Coleman Obasaju, David Gandara, et al.
Future Oncology (London, England)
|
April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Solange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
JAMA Oncology
|
September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Leora Horn, Ziping Wang, Gang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Page
of 44